Sputnik V has been authorised in 70 countries with a total population of 4 billion people





Sputnik V

entity of Bosnia and Herzegovina

RDIF actively cooperates with **24 production partners in 14 countries** which are already **producing Sputnik V vaccine**, including:



Iran
Italy
South Korea
Argentina
Kazakhstan



Sputnik V is one of the most effective COVID-19 vaccines in the world



Sputnik V's real-world efficacy against infection, according to analysed data from 3.8 mn vaccinated Russians

-C NO serious adverse events or vaccination-related deaths

-C NO hospitalization, cerebral venous thrombosis (CVT) cases or cases of myocarditis after vaccination

Source: Gamaleya Research Centre for Epidemiology and Microbiology. April 19, 2021

Sputnik V

Sputnik V demonstrates high efficacy against the Delta variant in Russia:



Sputnik V is 83.1% effective against infection by Delta variant with **6x reduction in infection risk**



Sputnik V is 94.4% effective against hospitalizations with **18x reduction in hospitalisation risk**

Also **highly protective against other new variants** of COVID-19, as confirmed by the publication in **the Vaccines**

Sputnik V demonstrated high safety and efficacy during the vaccination campaign in UAE Based on analysis of over 81,000 vaccinated individuals

97.8% efficacy against infection after the 2nd shot **100% efficacy against severe COVID-19 cases**

C NO serious adverse events or vaccination-related deaths
 C NO hospitalization, cerebral venous thrombosis (CVT) cases or cases of myocarditis after vaccination

Source: UAE Ministry of Health. June 8, 2021

UAE

S-putnik V

Sputnik V showed **high safety and** efficacy in **Bahrain**

Based on analysis of over 5,000 vaccinated individuals

94.3% efficacy against infection* **98.6%** of all COVID-19 cases were mild*

-C NO serious adverse events, cerebral venous thrombosis cases or vaccine-related deaths

* 14 days after the 2nd shot Source: Bahrain Ministry of Health. June 10, 2021


Sputnik V

Sputnik V became the most efficient vaccine against hospitalizations with COVID-19 in San Marino

94.8% efficacy against infection95.9% efficacy against hospitalizations

S-putnik V

HUNGARY



-C NO cerebral venous thrombosis (CVT) cases or vaccination-related deaths

Source: Government of Hungary. April 25, 2021

S-putnik V

Sputnik V showed the **best safety** during the vaccination campaign in the Buenos Aires region (Argentina)

 The lowest rate of serious adverse events (hospitalizations): almost 5 times lower compared to Covishield / AstraZeneca and lower compared to Sinopharm



<u>Soutnik V</u>


Source: Ministry of Health of the Province of Buenos Aires (Argentina)

A recent study in Argentina also shows that Sputnik V has a long-lasting protection, which even increases over 4-6 months following the vaccination

Sources: study «Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination»

ARGENTINA

Sputnik V (and its first component - Sputnik Light), became a significant part of immunization campaign in **Argentina**



Source: JHU CSSE COVID-19 Data

Sputnik V

Sputnik V demonstrates the highest safety with the lowest ratio of serious adverse events in Mexico

Based on analysis of over 36 mn administered doses. No link between vaccination and serious adverse events was found



Sputnik Light, as the first component of Sputnik V, is safe and highly effective as demonstrated by real-world data in a number of countries

78.6-83.7% efficacy against infection among the elderly in Argentina

93.5% efficacy against infection during the vaccination campaign in Paraguay

Best safety in Paraguay (based on analysis of over 320,000 subjects):

- ·C NO serious adverse events or vaccination-related deaths
- NO cerebral venous thrombosis (CVT) cases, Guillain-Barre syndrome (GBS) cases or cases of myocarditis or pericarditis after vaccination

Sources: Ministry of Health of the Buenos Aires province (Argentina), Ministry of Health of Paraguay

Sputnik Light as a stand-alone one-shot vaccine demonstrated effective protection against infection by Delta variant

70%75%efficacy againstefficacy in the ageinfection by Deltagroup below 60higher than that of most two-shot vaccines

over

D Efficacy against hospitalization and severe disease is even higher

Based on real data from 28,000 individuals who had been given a single dose of Sputnik Light as compared with a control group of 5.6 million unvaccinated individuals







